A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
This study will evaluate the efficacy and safety of ALKS 5461.
Inclusion Criteria:
Exclusion Criteria:
Washington DC, Maryland 20016, United States